STRESS BIOMARKERS IN SLEEP APNEA

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 患有睡眠呼吸暂停的患者患心血管疾病的风险增加。值得注意的是，与睡眠呼吸暂停相关的呼吸暂停和低氧血症事件与代谢活动的改变(即葡萄糖耐量和异甘醇抵抗)、全身炎症反应的增加和活性氧物种的增加有关，所有这些都可能增加心血管疾病的风险。然而，睡眠呼吸暂停患者夜间呼吸暂停发作与心血管疾病之间的关系尚未阐明。该方案的主要目的是确定睡眠呼吸暂停是否与伴有和不伴有心力衰竭的患者的代谢、炎症和心血管应激增加有关。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Patients with sleep apnea are at increased risk for cardiovascular disease. Notably, apneic and hypoxemic events associated with sleep apnea have been linked to alterations in metabolic activity (i.e., glucose intolerance adn isulin resistance), increases in the systemic inflammatory response and an increase in reactive oxygen species, all of which could potentially increase the risk of cardiovascular illness. However, the relationship between nocturnal apneic episodes and cardiovascular disease in patients with sleep apnea has not been elucidated. The primary objective of this protocol is to determine whether sleep apnea is associated with an increase in metabolic, inflammatory and cardiovascular stress in patients with and without heart failure.